Regenerate Vital Myocardium by Vigorous Activation of Bone Marrow Stem Cells - REVIVAL-3


Ex vivo studies have demonstrated a protective effect of human recombinant erythropoietin on ischemia and reperfusion. The REVIVAL-3 study sought to study the safety and efficacy of erythropoietin in reducing infarct size in patients with ST-segment elevation myocardial infarction (STEMI).